PDGFRB and sarcoma: Mismatched diagnoses have been suspected in another clinical trial involving rare cancers, the multi-institutional clinical trial regarding imatinib treatment for c-KIT or platelet-derived growth factor receptor (PDGFR)-positive sarcoma (Sugiura et al. 2010).